| Patents for A61P 27 - Drugs for disorders of the senses (53,017) |
|---|
| 02/06/2002 | CN1334097A Health-care product for improving visual function |
| 02/06/2002 | CN1334085A Application of tetracyclines antibiotics in preparing medicine to treat retinal ischemic injury |
| 02/05/2002 | US6344562 Thiazole derivatives |
| 02/05/2002 | US6344485 Method for treating glaucoma |
| 02/05/2002 | US6344479 Amino acid salt of ibuprofen |
| 02/05/2002 | US6344463 Skin disorders, acne |
| 02/05/2002 | US6344455 Treating cancer, atherosclerosis, restenosis, endometriosis, and psoriasis |
| 02/05/2002 | US6344450 Lactam compounds and their use as inhibitors of serine proteases and method |
| 02/05/2002 | US6344438 Therapeutic/cosmetic compositions comprising CGRP antagonists for treating the eyes or eyelids |
| 02/05/2002 | US6344321 Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met |
| 02/05/2002 | US6344210 Composition for freshening nostrils and sinus cavities |
| 01/31/2002 | WO2002008396A2 Human proteases |
| 01/31/2002 | WO2002008285A2 Il-17 molecules and uses thereof |
| 01/31/2002 | WO2002008268A2 Leucine-based motif and clostridial neurotoxins |
| 01/31/2002 | WO2002008255A2 Cell cycle proteins and mitosis-associated molecules |
| 01/31/2002 | WO2002008232A1 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists |
| 01/31/2002 | WO2002008231A2 Biologically active macrolides, compositions, and uses thereof |
| 01/31/2002 | WO2002008221A2 Capsaicin receptor ligands |
| 01/31/2002 | WO2002008219A2 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission |
| 01/31/2002 | WO2002008218A1 Cyclic substituted aminomethyl compounds and medicaments containing said compounds |
| 01/31/2002 | WO2002008217A2 COUMARIN DERIVATIVES USEFUL AS TNFα INHIBITORS |
| 01/31/2002 | WO2002008213A1 Colchinol derivatives as angiogenesis inhibitors |
| 01/31/2002 | WO2002008210A1 Cyanomethyl substituted thiazoliums and imidazoliums and treatments of disorders associated with protein aging |
| 01/31/2002 | WO2002008188A1 N-substituted indoles useful in the treatment of diabetes |
| 01/31/2002 | WO2002008186A2 Cyclopentanoindoles, compositions containing such compounds and methods of treatment |
| 01/31/2002 | WO2002008185A1 Pyrrolidine derivatives as metalloprotease inhibitors |
| 01/31/2002 | WO2002008178A1 New combination of serotonin agonist (5ht2) and antagonist (5ht6)as pharmaceutical formulation |
| 01/31/2002 | WO2002007737A1 Method for the treatment of glaucoma and ocular hypertension by administering nucleotides |
| 01/31/2002 | WO2002007731A2 Composition containing a 15-keto prostaglandin compound for treating of ocular hypertension and glaucoma |
| 01/31/2002 | WO2002007730A1 Alpha v integrin receptor antagonists |
| 01/31/2002 | WO2002007725A1 Method for treating fibrotic diseases or other indications ic |
| 01/31/2002 | WO2002007678A2 Mu-conopeptides |
| 01/31/2002 | WO2001074381A3 Calpain inhibitors in cancer treatment |
| 01/31/2002 | WO2001070668A3 Amines substituted with a dihydronaphthalenyl, crhomenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity |
| 01/31/2002 | WO2001064870A3 Mutated cyclin g1 protein |
| 01/31/2002 | WO2001062775A3 Novel antiarrhythmic peptides |
| 01/31/2002 | WO2001038503A3 Novel human protein kinases and protein kinase-like enzymes |
| 01/31/2002 | WO2001008634A3 Polynucleotide encoding a human serine protease |
| 01/31/2002 | US20020013369 Certain 5-alkyl-2arylaminophenylacetic acids and derivatives |
| 01/31/2002 | US20020013357 Valdecoxib compositions |
| 01/31/2002 | US20020013353 Blocking of associated non-inactivating sodium channels in retinal ganglion cells in order to limit sodium/calcium exchange in retinal ganglion cells and prevent buildup of calcium level in retinal ganglion cells to a lethal level |
| 01/31/2002 | US20020013347 Tri-aryl-substituted-ethane PDE4 inhibitors |
| 01/31/2002 | US20020013341 For therapy of acute infection, acute phase response, age related macular degeneration, alcoholism, anorexia, asthma, autoimmune disease, autoimmune hepatitis, Bechet's disease, cachexia, calcium pyrophosphate dihydrtate deposition |
| 01/31/2002 | US20020013336 Fused heterocyclic compounds and their use in the treatment of neurodegenerative diseases |
| 01/31/2002 | US20020013333 As inhibitors of matrix metalloproteinase, for therapy of diseases such as degenerative diseases and certain cancers |
| 01/31/2002 | US20020013311 Of the eye, nose, skin, ear, gastrointestinal tract, airways or lung and preventing or treating manifestations of systemic mastocytosis |
| 01/31/2002 | US20020013294 Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
| 01/31/2002 | US20020013293 Phospholipids of hydroxyeicosatetraenoic acid-like derivatives and methods of use |
| 01/31/2002 | US20020013278 Using an interleukin-1 beta converting enzyme inhibitor pro-drug to treat apoptosis-, interferon-gamma inducing factor or interferon-gamma inducing diseases; antiinflammatory and -proliferative agents; autoimmune/degenerative disesesdiseases |
| 01/31/2002 | US20020013259 Therapeutic and diagnostic methods for ulcerative colitis and associated disorders |
| 01/31/2002 | US20020012992 Production of adenine nucleotide translocator (ANT), novel ANT ligands and screening assays therefor |
| 01/31/2002 | US20020012700 Portion of pseudoephedrine is contained in core whereby release into environment of use is sustained, cetirizine is contained as immediate-release component; antiallergens, spasmolytics |
| 01/31/2002 | CA2416988A1 Leucine-based motif and clostridial neurotoxins |
| 01/31/2002 | CA2416751A1 Alpha v integrin receptor antagonists |
| 01/31/2002 | CA2416691A1 Proteases |
| 01/31/2002 | CA2416681A1 Composition for treatment of ocular hypertension and glaucoma |
| 01/31/2002 | CA2416544A1 Mu-conopeptides |
| 01/31/2002 | CA2415742A1 N-substituted indoles useful in the treatment of diabetes |
| 01/31/2002 | CA2415740A1 Pyrrolidine derivatives as metalloprotease inhibitors |
| 01/31/2002 | CA2415606A1 Capsaicin receptor ligands |
| 01/31/2002 | CA2415585A1 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission |
| 01/31/2002 | CA2415362A1 Method for treating fibrotic diseases or other indications |
| 01/31/2002 | CA2415196A1 Cyclic substituted aminomethyl compounds and medicaments comprising these compounds |
| 01/31/2002 | CA2415077A1 Cell cycle proteins and mitosis-associated molecules |
| 01/31/2002 | CA2415054A1 Cyanomethyl substituted thiazoliums and imidazoliums and treatments of disorders associated with protein aging |
| 01/31/2002 | CA2412626A1 Il-17 molecules and uses thereof |
| 01/31/2002 | CA2411192A1 Combination of serotonin agonist (5ht2) and antagonist (5ht6)as a pharmaceutical formulation |
| 01/31/2002 | CA2410562A1 Colchinol derivatives as angiogenesis inhibitors |
| 01/30/2002 | EP1175446A1 Human antibodies that bind human il-12 and methods for producing |
| 01/30/2002 | EP1175445A1 Specific antibodies and antibody fragments for tgfbeta1 |
| 01/30/2002 | EP1175440A1 48 human secreted proteins |
| 01/30/2002 | EP1175417A1 Substituted benzolactam compounds |
| 01/30/2002 | EP1175412A1 Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents |
| 01/30/2002 | EP1175400A1 Renin inhibitors |
| 01/30/2002 | EP1175383A1 Glucocorticoid receptor modulators |
| 01/30/2002 | EP1175223A2 Methods and compositions for modulating an immune response |
| 01/30/2002 | EP1175222A2 Monthly doses of glycopeptide antibiotics for treatment of streptococcus pneumoniae infections |
| 01/30/2002 | EP1175218A1 Ocular therapy in keratoconjuctivitis sicca using topically applied androgens or tgf-beta |
| 01/30/2002 | EP1175216A2 Antimalarian agents for the treatment of asthma |
| 01/30/2002 | EP1175214A2 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect |
| 01/30/2002 | EP1091746B1 Use of iso-osmotic saline solutions for preparing cerumenolytic medicines |
| 01/30/2002 | EP0934267B1 Alpha-amino sulfonyl hydroxamic acids as matrix metalloproteinase inhibitors |
| 01/30/2002 | EP0832198A4 Oxygen activatable formulations for disinfection or sterilization |
| 01/30/2002 | EP0777480A4 Optic nerve health |
| 01/30/2002 | CN1333755A Benzimidazole compounds that are vitronectin receptor antagonists |
| 01/30/2002 | CN1333686A Clathrates of dehydroepiandrosterone and corresponding pharmaceutical compositions |
| 01/30/2002 | CN1333677A Composition set and kit for use in intraocular surgery |
| 01/30/2002 | CN1333339A Polytype gene of MXA protein and application thereof |
| 01/30/2002 | CN1333020A Biochemical material composition for preventing and treating disease caused by smooth muscle cell contraction in human organ |
| 01/30/2002 | CN1333018A Medicine for treating immune relative disease of anterior chamber and surface of eye |
| 01/30/2002 | CN1078464C Medicinal composition for preventing and curing xerophthalmia and disease led themby, method and apparatus |
| 01/29/2002 | US6342584 Antiproliferative, anticarcinogenic, antitumor, antiinflammatory, and antimetastasis agents; diabetes, restenosis, rheumatoid arthritis treatment; genetic engineering |
| 01/29/2002 | US6342525 Benzenoid derivatives of 15-hydroxyeicosatetraenoic acid and methods of their use in treating dry eye disorders |
| 01/29/2002 | US6342524 Use of non-steroidal anti-inflammatory agents in combination with compounds that have FP prostaglandin agonist activity to treat glaucoma and ocular hypertension |
| 01/29/2002 | US6342521 3-(arylsulfonylamino)-tetrahydrofuran-3-carboxylic acid hydroxamides |
| 01/29/2002 | US6342510 Antiinflammatory agents and enzyme inhibitors |
| 01/29/2002 | US6342505 Use of 4-substituted tetrahydropyridines for making medicines acting on TGF-β1 |
| 01/29/2002 | US6342221 Antibody conjugate compositions for selectively inhibiting VEGF |
| 01/29/2002 | US6342219 As anti-angiogenic and in tumor therapy |
| 01/29/2002 | CA2031368C Composition comprising non-steroidal non-inflammatory agent and effectively non-antibacterial tetracycline |